ATS Corporation

Elysium's MatchHub will bridge OTC Link ATS and digital asset custodians, closing the interoperability gap between market structures Elysium's MatchHub will bridge OTC Link ATS and digital asset custodians, closing the interoperability gap between market structures

globenewswire.com - 2026-07-15 07:00:00

Kayan Project, Veea Inc. and Panoptes PBC turn AI into humanity's force multiplier for the preservation of natural environments and sustainable communities Kayan Project, Veea Inc. and Panoptes PBC turn AI into humanity's force multiplier for the preservation of natural environments and sustainable communities

globenewswire.com - 2026-07-06 23:25:00

GREENWICH, Conn.--(BUSINESS WIRE)-- #IBKR--Interactive Brokers (Nasdaq: IBKR) announced the launch of select Korean equities through Nextrade.

businesswire.com - 2026-06-30 10:00:00

Investors need to pay close attention to ATS stock based on the movements in the options market lately.

zacks.com - 2026-06-22 11:55:32

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. (NASDAQ: FUSE), a leading provider of enterprise AI products and services, today announced expanded enterprise access to its Agentic AI for Talent Acquisition platform through new connectivity with more than 30 enterprise applicant tracking systems (ATS), enabling Fusemachines Agents to work directly within the systems organizations already use to manage talent and hiring. This expanded connectivity represents the first in a broader series of planned platform enhancements designed to bring AI-powered recruiting capabilities closer to the workflows, data, and systems recruiters rely on every day.

globenewswire.com - 2026-06-18 08:30:00

Not intended for UK and US audiences  Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses. Based on the modeling, nerandomilast consistently increased median survival in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).1,2 Modeling predicts meaningful extensions in survival with nerandomilast, including a multi-year increase in median survival when used as monotherapy, and additional gains when added to standard treatment.1,2 Ingelheim, Germany - Long-term survival modeling of Boehringer Ingelheim's oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis (IPF) and up to 3.3 years in adults with progressive pulmonary fibrosis (PPF), compared with no therapy.1,2 These findings are based on data from the Phase III FIBRONEER™ trials and were recently presented at the ATS and EULAR 2026 international congresses.

globenewswire.com - 2026-06-18 04:05:00

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Anne Cybulski, Interim Chief Financial Officer, will participate in the Stifel Summer Solstice Conference in Muskoka, ON on June 16, 2026. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Stifel representative or [email protected]. About ATS Corporation ATS Corporation is an industry-leading automation s.

businesswire.com - 2026-06-08 17:00:00

ATS NYSE: ATS reported higher fiscal 2026 revenue and adjusted earnings from operations, while outlining a series of restructuring actions aimed at improving margins, cash generation and capital efficiency heading into fiscal 2027.

marketbeat.com - 2026-05-28 12:10:41

ATS (ATS) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.28 per share a year ago.

zacks.com - 2026-05-28 08:16:09

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and twelve months ended March 31, 2026. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Fourth quarter highlights: Revenues were $747.1 million (adjusted revenues1 $744.3 million) compared to $574.2 million (adjusted revenues $721.1 million) a year ago. Net loss was $16.2 million compared.

businesswire.com - 2026-05-28 06:00:00

Entravision Communications has transformed into a high-growth ad-tech platform, with ATS now driving the majority of revenue and profitability. ATS delivered 204% year-over-year revenue growth and 22% EBIT margins in Q1 2026, highlighting strong scalability and operating leverage. EVC trades at broadcasting multiples despite ad-tech-like growth and margins, suggesting further upside if ATS sustains momentum.

seekingalpha.com - 2026-05-21 06:25:59

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced new clinical and translational data presented at the American Thoracic Society (ATS) International Conference 2026 and the simultaneous publication in Clinical Immunology Communications 1 describing the use of sequential immunotherapy with MiNK's off-the-shelf iNKT cell therapy, agenT-797 and N-803, an IL-15 superagonist, in a critically ill patient with unresolving disseminated Coccidioides immitis infection, severe acute respiratory distress syndrome, and concurrent hospital-acquired Pseudomonas aeruginosa pneumonia.

globenewswire.com - 2026-05-20 11:07:00

SAN FRANCISCO and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that it will present multiple clinical and preclinical data from IBI3002(IL-4Rα/TSLP), IBI3038(IGF-1R/IL-6), IBI3031(IGF-1R/TSHR) at the 2026 American Thoracic Society (ATS) International Conference, held in Orlando, Florida (US) from May 17–20 and the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held in Denver, Colorado (US) from May 3-7. ATS Presentation Title： IBI3002, A First-in-class Anti-IL-4Rα/TSLP Bispecific Antibody in Patients with Mild-To-Moderate Asthma: A Randomized, Double-Blind, Placebo-Controlled, Single Dose Phase Ib Study Abstract Number：8579 Presentation Form: Poster Author：Dr. Yuanfang Ren, Innovent Biologics IBI3002 is a first-in-class bispecific antibody that simultaneously targets IL-4Rα and its upstream inflammatory cytokine―thymic stromal lymphopoietin (TSLP), a key cytokine involved in initiating and perpetuating the inflammatory response in the airways.

prnewswire.com - 2026-05-18 20:00:00

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of Medicine has published the full results of its TETON-1 study, as well as combined analyses of its TETON-1 and TETON-2 studies, evaluating the use of nebulized Tyvaso for the treatment of IPF. The publication is available here. A summary of the publication was also presented today during a symposium at th.

businesswire.com - 2026-05-18 16:15:00

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

globenewswire.com - 2026-05-18 15:30:00

– Verekitug led to statistically significant and clinically meaningful improvement in asthma symptom control as measured by the Asthma Control Questionnaire-6 (ACQ-6) in participants with CRSwNP and comorbid asthma –

globenewswire.com - 2026-05-18 11:30:00

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being presented today during the Breaking News: 2026 Clinical Trial Results in Pulmonary Medicine session at the annual meeting of the American Thoracic Society (ATS) International Conference in Orlando. Ralinepag has not been approved for use in any indication by the U.S. Food and Dr.

businesswire.com - 2026-05-17 14:15:00

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the fourth quarter ended March 31, 2026, before markets open on Thursday May 28, 2026. At 8:30 a.m. Eastern on May 28, 2026, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/406309619 and th.

businesswire.com - 2026-05-14 17:00:00

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 20.

businesswire.com - 2026-05-11 16:05:00

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve.

businesswire.com - 2026-05-11 06:30:00

Polarean highlights 20+ ATS 2026 presentations advancing Xenon MRI as a biomarker platform for trials, treatment response, and pediatric lung disease.

globenewswire.com - 2026-05-07 08:44:00

Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug–drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it will deliver an oral presentation and present multiple abstracts at the American Thoracic Society (ATS) 2026 International Conference, taking place from May 15 – 20, 2026, in Orlando, Florida.

globenewswire.com - 2026-04-30 16:05:00

ATS (ATS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-04-27 13:11:15